Research Paper Volume 15, Issue 9 pp 3331—3355
In vitro and in vivo effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers
Figure 4. In silico analysis indicates the senolytic/senomorphic activity of zoledronic acid. (A) Volcano plot showing the differentially regulated genes between control and zoledronic acid treatments. (B) The SenMayo and (C) Fridman senescene/SASP gene sets indicate a downregulation of senescence-associated pathways in the zoledronic acid group, and (D) the hallmark of inflammatory response as well as (E) Interleukin 1 signaling also indicate a lower inflammatory activity in the zoledronic acid group. p-values are using one-way ANOVA with multiple comparisons, adjusted with the Tukey post-hoc method. N=8 mice in the Control and n=7 in the zoledronic acid group.